Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Chris Burns, Terrie-Anne Cock, Anthony Bishop, Nicole Kruger, Sarah McCormack, Sumitra Ananda, Marion Harris, Warren Lance Joubert, Jin Won Kim, Choong-kun Lee, Woo Jin Lee, Larissa Rachel Lipton, Adnan Nagrial, Do-Youn Oh, Joon Oh Park, Nick Pavlakis, Jason Lickliter
Institutions: Sunshine Hospital, Monash Health, Greenslopes Private Hospital, Seoul National University, Seoul National University Bundang Hospital, Yonsei Cancer Hospital, National Cancer Center, National Cancer Center Hospital, Western Health, Westmead Hospital, Seoul National University Hospital, Samsung Medical Center, Sungkyunkwan University, GenesisCare
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400414192